遺伝的個体差要因も含めた薬物間相互作用  [in Japanese] Drug-Drug Interactions with Consideration of Pharmacogenetics  [in Japanese]

Access this Article

Author(s)

Abstract

 Elderly patients often suffer from a variety of diseases and therefore may be prescribed several kinds of drugs. Interactions between these drugs may cause problems in some patients. Guidelines for drug interactions were released on July 8, 2014 “Drug Interaction Guideline for Drug Development and Labeling Recommendations (Final Draft)”. These guidelines include the theoretical basis for evaluating the mechanisms of drug interaction, the possible extent of drug interactions, and take into consideration special populations (<i>e.g</i>., infants, children, elderly patients, patients with hepatic or renal dysfunction, and subjects with minor deficient alleles for drug metabolizing enzymes and drug transporters). In this symposium article, I discuss this last special population: altered drug metabolism and drug interactions in subjects with minor alleles of genes encoding deficient drug metabolizing enzymes. I further discuss a drug label for eliglustat (Cerdelga) with instructions for patients with ultra-rapid, extensive, intermediate, and poor metabolizer phenotypes that arise from different CYP2D6 gene alleles.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 138(3), 365-371, 2018

    The Pharmaceutical Society of Japan

Codes

  • NII Article ID (NAID)
    130006410754
  • NII NACSIS-CAT ID (NCID)
    AN00284903
  • Text Lang
    JPN
  • ISSN
    0031-6903
  • NDL Article ID
    028891464
  • NDL Call No.
    Z19-411
  • Data Source
    NDL  J-STAGE 
Page Top